Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Carlos Rodriguez-Fierro

Cardiovascular Disease Marrero, LA Medical Doctor

NPI 1740289727 CMS profile 169468

1111 Medical Center Blvd, Suite S-350, Marrero, LA 70072

Open in the dashboard

General payments

$12,775

341 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Carlos Rodriguez-Fierro of Marrero, LA is reported in the CMS Open Payments database as having received $12,775 across 341 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 84th percentile of Cardiovascular Disease profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $3,251 63
2024 General $1,392 61
2023 General $2,208 48
2022 General $811 32
2021 General $1,405 28
2020 General $807 7
2019 General $2,901 102

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Carlos Rodriguez-Fierro
  • Cardiovascular Disease median
  • Middle half of Cardiovascular Disease
  • National median

In program year 2025, general payments to Carlos Rodriguez-Fierro were reported at $3,251. Among 16,617 Cardiovascular Disease profiles paid that year, the median was $432 and the middle half received between $132 and $1,252.

Show as a table
Year Carlos Rodriguez-Fierro Cardiovascular Disease median Middle half National median
2019 $2,901 $450 $127–$1,392 $163
2020 $807 $242 $77–$751 $114
2021 $1,405 $335 $101–$1,037 $132
2022 $811 $395 $121–$1,211 $149
2023 $2,208 $443 $136–$1,283 $160
2024 $1,392 $450 $136–$1,323 $164
2025 $3,251 $432 $132–$1,252 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Medtronic, Inc. $4,204 34 payments
  2. Medtronic Vascular, Inc. $1,073 9 payments
  3. Janssen Pharmaceuticals, Inc $923 32 payments
  4. E.R. Squibb & Sons, L.L.C. $728 23 payments
  5. Amgen Inc. $695 27 payments
  6. Novartis Pharmaceuticals Corporation $651 52 payments
  7. Merck Sharp & Dohme Corporation $390 23 payments
  8. Sanofi-Aventis U.S. LLC $348 13 payments
  9. Pfizer Inc. $314 8 payments
  10. Esperion Therapeutics, Inc. $288 12 payments
  11. Other $3,162 108 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $11,581 328 payments
  2. Travel and Lodging $1,159 7 payments
  3. Education $36 6 payments
Products named General payments · program years 2019–2025
  1. Micra Pacemakers $1,058 9 payments
  2. XARELTO $923 32 payments
  3. AZURE XT DR MRI SURESCAN $666 6 payments
  4. Repatha $637 24 payments
  5. VERQUVO $495 29 payments
  6. LINQ II $477 4 payments
  7. Resolute $403 3 payments
  8. LEQVIO $392 36 payments
  9. MICRA Pacemakers $334 3 payments
  10. COBALT DR MRI SURESCAN $303 2 payments
  11. Other $6,584 221 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 69 drugs

Part D claims

9,967

Median for Internal Medicine: 777

Drug cost

$1,642,022

Median for Internal Medicine: $73,373

Branded share of claims

29.4%

Median for Internal Medicine: 19.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Eliquis Apixaban Brand 641 $548,383
Repatha Sureclick Evolocumab Brand 361 $303,476
Entresto Sacubitril/Valsartan Brand 218 $228,184
Xarelto Rivaroxaban Brand 196 $182,762
Praluent Pen Alirocumab Brand 110 $79,060
Nexletol Bempedoic Acid Brand 73 $45,267
Vascepa Icosapent Ethyl Brand 88 $43,351
Jardiance Empagliflozin Brand 46 $33,957
Repatha Syringe Evolocumab Brand 31 $22,586
Ranolazine Er Ranolazine Brand 249 $17,977

The 10 drugs with the highest cost, of 69 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 104,182 Part D prescribers listed as Internal Medicine; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 37 billing codes

Paid by Medicare

$46,250

Medicare's payments for the services billed

Medicare patients

320

Average age 74

Services billed

1,452

176 women, 144 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Ischemic heart disease 53%
Diabetes 42%
Arthritis 41%
Chronic kidney disease 33%
Atrial fibrillation 27%
Heart failure 23%
COPD 15%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 15 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
ONPATTRO
$243 — —
LEQVIO
$203 — —
WAINUA
$118 — —
VERQUVO
$105 25 —
ENTRESTO
$80 218 —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 15 in the dashboard with a free account

Records

341 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Cardiovascular Disease in Louisiana

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record